Locations:
Search IconSearch
August 5, 2015/Neurosciences

Epilepsy: A Conversation with Imad Najm, MD

Options for patients not responsive to medication

DrNajm_690x380

When it comes to epilepsy, many patients see primary care physicians (PCPs) and receive appropriate care. But sometimes, a patient needs to see a doctor who specializes in epilepsy treatment. That’s where the Cleveland Clinic Epilepsy Center can help. “There is a need for a thorough evaluation for suspected seizures,” says Imad Najm, MD, Director of the Epilepsy Center. “It is very appropriate for the PCP to decide there is need for further workup.”

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

When should PCPs refer patients to the epilepsy center?

If the PCP feels comfortable with the treatment, he or she can continue care. If there are any lesions on the brain shown on a high-resolution MRI, it is appropriate to refer the patient to a neurologist. If the patient does not respond to one or more appropriately chosen anti-epileptic medications, we can comfortably advise the PCP to recommend that the patient see an epilepsy specialist.

What does it mean if an anti-epileptic medication fails to control the patient’s seizures?

If a patient fails anti-epileptic medication(s), one possibility is that the patient may not have epilepsy. In these cases, the diagnosis of pseudo seizures or nonepileptic seizures may be made and an appropriate treatment protocol implemented. The second possibility is that the patient has epilepsy, but it is “pharmacoresistant.” The recommendation is for the patient to be admitted to the epilepsy monitoring unit (EMU), where valuable electroencephalography (EEG) and video/semiological data regarding the seizure(s) are acquired. This evaluation will accomplish a key goal: to confirm the diagnosis of epilepsy or rule it out. If an epilepsy diagnosis is confirmed, we next determine if the epilepsy is coming from a single, well-defined area of the brain. We find out if this patient has focal epilepsy that can be targeted with surgery. In such situations, surgery is effective for controlling seizures completely in 60 to 80 percent of the patients.

What can your patient expect during an initial visit?

Advertisement

During an initial evaluation, a detailed history is taken, including information regarding the type of feeling experienced before seizures (so-called auras) and what type of behavior is exhibited during a seizure. Any tests done (including MRI and EEG) to date will also be reviewed. Our multidisciplinary team will then meet in a group setting to map out the most appropriate treatment plan, considering both medical and surgical options.

What options are there for epilepsy that doesn’t respond to medications?

Today, we have more options than ever before. Sometimes, implanting a vagus nerve stimulation device helps control seizures — in particular, for patients who have seizures activity in areas that are too critical to functioning to risk surgery. Another possible and exciting option is switching patients (in particular children) to a ketogenic diet or a modified Atkins diet (high fat, low carbohydrate, adequate protein). About half of the patients on this diet have more than a 50 percent reduction in the number of seizures; 20 to 30 percent may have more than a 90 percent reduction in seizures. Less than 10 percent of patients on the ketogenic diet may have no seizures at all.

Photos ©Russell Lee

Advertisement

Related Articles

Man having fretful sleep
Certain Antidepressants Increase REM Sleep Without Atonia

Specificity in study criteria yields sleep disorder insights

dr. daniel ontaneda against a decorative background
October 2, 2024/Neurosciences/Podcast
Takeaways From the New Diagnostic Criteria for Multiple Sclerosis (Podcast)

A co-author explains some of the key McDonald criteria revisions

middle-aged woman leaning against porch railing
First Evidence of Delayed Disability Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis

The BTK inhibitor tolebrutinib meets its primary endpoint in phase 3 HERCULES trial

neuron affected by multiple sclerosis
Let’s Move From Categorizing MS by Clinical Phenotype to Underlying Disease Mechanisms

Meaningful characterization is critical to advancing research and care, review authors contend

heads of an adolescent boy and man in his fifties
When Multiple Sclerosis Is Suspected in Patients Under 18 or Over 50

Guidance from international committee on differential diagnoses and diagnostic approach

Dr. Imad Najm against a decorative background
September 16, 2024/Neurosciences/Podcast
Temporal Lobe Epilepsy and the Potential of Gene Therapy (Podcast)

Investigational gene approaches offer hope for a therapeutically challenging condition

researcher in dark laboratory
September 12, 2024/Neurosciences/Research
Preclinical Imaging Research Aims to Help Refine Deep Brain Stimulation for Stroke Recovery

$3.2 million grant will fund use of calcium-based imaging to record neuronal activity in ischemia model

ambulance on rural road
September 6, 2024/Neurosciences/Cerebrovascular
Study Sheds Light on the Process Metrics Driving Rural Inequity in Stroke Care

Findings from large cohort analysis can guide ongoing quality improvement initiatives

Ad